PharmaCielo has made an initial shipment of CBD Isolate to a pharmaceutical company in Morocco to facilitate pre-commercial testing. The customer is developing a portfolio of cannabinoid medicines, both non-psychoactive and psychoactive.
Management commentary
Bill Petron, CEO of PharmaCielo, commented, "With our first shipment to Morocco, PharmaCielo products are now at various stages of testing and sales with customers in 12 countries globally. This customer provides us with both our first potential relationship in Africa, as well as an additional gateway to the EU market. Our business development team has done an outstanding job of getting PharmaCielo into the testing and auditing phases at several large potential customers, and we expect this activity to translate into commercial deals in the coming months, paving the way to significant revenue growth for the Company."
For more information:
PharmaCielo
[email protected]
www.pharmacielo.com